Associate
Chiaki Kobayashi practices all aspects of intellectual property law, including client counseling, prosecution, opinion preparation, due diligence investigations, litigation, and post-grant review proceedings related to the chemical, biotechnology, and pharmaceutical fields.
With her fluency in Japanese and cultural appreciation, Chiaki has significant experience counseling Japanese clients on strategic intellectual property development, patent portfolio management, due diligence, patent prosecution, litigation, and pre-litigation strategies. She frequently lectures on intellectual property issues affecting Japanese companies and their global businesses. Chiaki participates in local professional associations, such as the Licensing Executives Society of Japan. She has extensive experience in litigation involving Japanese parties, and she routinely works with in-house counsel and vendors to reduce the burden of U.S. litigation on Japanese clients.
Chiaki's experience includes numerous aspects of patent litigation, including coordinating discovery, developing infringement and invalidity strategies, preparing fact and technical expert witnesses, drafting a wide range of motions and briefs, and taking and defending depositions. She has particular experience in representing pharmaceutical patent holders in litigation arising under the Hatch-Waxman Act.
While in law school, Chiaki worked at Finnegan as a summer associate and as a law clerk. As an undergraduate, she assisted in research on lipid metabolism using Nile-rat models.
Senju Pharmaceutical Co.; Bausch + Lomb v. Lupin Ltd.
Represented Senju and Bausch + Lomb in Hatch-Waxman patent infringement litigation concerning multiple ANDAs for generic versions of Prolensa®. Secured a permanent injunction against generic defendants.
1:14-cv-00667, -04149; 1:15-cv-00335; 1:16-cv-01097, D.N.J., Judges Goodman, Shipp, Simandle, Williams
Secured a permanent injunction against generic defendants on behalf of Bausch + Lomb, Mitsubishi Tanabe, Ube, and Senju in Hatch-Waxman patent infringement litigation concerning multiple ANDAs for generic versions of opthalmic drug Bepreve®.
1:14-cv-01325, D.N.J., Judges Arpert, Hillman, Schneider, Shipp
Commercial Copy Innovations, Inc. v. Mimaki USA, Inc. et al.
8:17-cv-00437, C.D. Cal., Judges Scott, Selna
Dow Pharmaceutical Sciences, Inc. v. Tolmar, Inc.
2:15-cv-07971, D.N.J., Judges Bongiovanni, Chesler, Waldor
Dow Pharmaceutical Sciences, Inc. v. Taro Pharmaceuticals U.S.A., Inc.
2:16-cv-00217; 2:17-cv-00544, -01568, D.N.J., Judges Chesler, Waldor
Event
General Information on English Contracts for Pharmaceutical Products General Information on English Contracts for Pharmaceutical Products
February 16, 2023
Webinar
Articles
Strategies for Parameter Patents in the United States Strategies for Parameter Patents in the United States
February 1, 2023
Intellectual Property ManagementEvent
Strategies and Ways to Avoid IP Pitfalls When Entering Joint Development Arrangements Strategies and Ways to Avoid IP Pitfalls When Entering Joint Development Arrangements
April 13, 2022
Webinar
"Chiaki Kobayashi shines at prosecution, litigation and counselling, especially when it comes to biotechnology and pharmaceuticals. Among her professional highlights is securing a permanent injunction against generics."
Intellectual Asset Management Patent 1000
"Chiaki Kobayashi shines at prosecution, litigation and counselling, especially when it comes to biotechnology and pharmaceuticals. Among her professional highlights is securing a permanent injunction against generics."
Intellectual Asset Management Patent 1000
Press Release
Finnegan Receives Top Rankings from Intellectual Asset Management; 46 Attorneys Ranked Finnegan Receives Top Rankings from Intellectual Asset Management; 46 Attorneys Ranked
June 30, 2023
Intellectual Asset ManagementDue to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.